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Abstract 
Background: Antineoplastic medicines are increasingly becoming more vital in many public 
health setups. There has been significant progress made in terms of newer molecules since the 
advent of chemotherapy. Despite the importance of antineoplastic medicines and advent of 
these molecules, there are still issues of limited availability and affordability in Zimbabwe. 
Currently the country has no government initiated policies on pricing and accessibility of 
antineoplastic medicines in public and private institutions, placing health care consumers at 
risk. A study was therefore designed to assess the price, availability and affordability of 
antineoplastic medicines in Harare Province, Zimbabwe.  
Methods: The study was based on the standardised method recommended by the World Health 
Organisation (WHO) and Health Action International (HAI). A data collection form-based 
cross-sectional survey was conducted in public and private medicine outlets.  A total of 153 
facilities were surveyed. The facilities consisted of three (3) public institutions and one hundred 
and fifty (150) private pharmacies in Harare and surrounding towns. The percentage 
availability, median price ratio using International Reference Prices, mark-ups, price and 
affordability of antineoplastic medicines were determined. Affordability was determined by 
using the wage of the lowest paid government worker which was USD296 per month. 
Median price ratios were calculated for twenty-two (22) of the antineoplastic medicines that 
were imported into the country from the import records at the Medicines Control Authority and 
also appearing on the medicines register for private pharmacies and seven (7) medicines for 
the public hospital pharmacies. The WHO’s International Reference Prices were used for 
calculation of median price ratios. Range, mode and average mark-up percentages for the 
antineoplastic medicines were also determined. Availability and price in the public sector was 
compared to availability in the private sector. Affordability was calculated as the out-of-pocket 
day’s wages to buy a monthly cycle of the antineoplastic medicine. 
Results: The percentage availability of the antineoplastic medicines at the government 
institutions was 25%, whilst the percentage availability of the antineoplastic medicines in the 
private sector ranged from 1% to 42.7%. Fifty percent of the twenty-two (22) medicines in the 
private sector had a median price ratio of lower than 4. The median price ratio in the private 
sector ranged from 0.60 to 11. Median price ratios were calculated for seven (7) medicines in 
the public sector. The median price ratio in the public sector ranged from 0.73 to 2.25. Eleven 
 
 
xi 
 
(11) of the medicines in the private sector were affordable with ten (10) days wage and below. 
Eight of the medicines were slightly affordable with wage days more than 10 days wage but 
less than 20 days wage. Wage days in private sector ranged from 1 day to 490 days. 
Affordability of the medicines in the public sector ranged from 1 to 10 days wage. Average 
percentage mark-up was 51.3% in the private sector and 34% in the public sector for the 
medicines that were available. 
Conclusion: Medicines were generally more available in the private sector than in the public 
sector. The government needs to continue supporting the National Pharmaceutical Company’s 
procurement of antineoplastic medicines. Generally medicines were more affordable in the 
public sector than in the private sector. The high percentage mark-ups calculated in the private 
sector compared to the public sector are as a result of the overhead expenses in private 
pharmacies which have to be borne from the actual sales of the medicines unlike in the public 
sector were the services are subsidised by the government. The low availability of 
antineoplastic medicines coupled with a very high unemployment rate means there is a huge 
burden on accessibility of antineoplastic medicines in Harare. Most patients cannot afford 
antineoplastic medicines which can result in increased mortality. There is a need to subsidise 
the medicines to improve accessibility. This will reduce the out-of-pocket expenses made by 
patients. There is a need to also ensure that medical insurance in Zimbabwe allow all 
pharmacies to retail antineoplastic medicines instead of the selective incorporation of 
pharmacies into their health insurance schemes. The calculated median price ratios range 
showed that the prices of the medicines are varied and there is need to have medicine 
procurement and pricing policies that minimise the median price ratio to lower than 5 for all 
antineoplastic medicines. 
Keywords: Affordability, antineoplastic medicines, availability, Zimbabwe  
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CHAPTER 1 INTRODUCTION 
 
Division of chapters 
The dissertation consists of four chapters as follows: 
 Chapter 1: Provides an introduction to the study as well as the aims, objectives and a 
brief overview of the methodology. 
 Chapter 2: Provides the literature background to the study. 
 Chapter 3: Presents the findings of the study. 
 Chapter 4: Consists of the discussion of the study, recommendations, limitations and 
strengths of the study. 
 Chapter 5: Consists of the conclusion of the study. 
 
1.0 Introduction  
This chapter explores the background and context of the study. This chapter discusses the 
current situation in Zimbabwe and how it affects the availability and affordability of 
antineoplastic medicines. The chapter discusses the rationale, aims and objectives and 
methodology used to address the research objectives in the study.  
1.1 Background and context of the study 
One of the Millennium Development Goals (MDGs) acknowledges the need to improve the 
availability of affordable medicines for all people in developing countries (WHO/HAI, 2008). 
This goal has been adopted into goal number 3 on good health well-being of the Sustainable 
Development Goals (United Nations, 2015).  Many initiatives have been put in place through 
the Global Fund, which mainly looks into three major diseases namely, HIV/AIDS, malaria 
and tuberculosis. However there has not been much attention on other critical non-
communicable diseases like cancer. There is no or little availability of antineoplastic medicines 
in all institutions through donor initiatives as is the case with the aforementioned conditions 
(National Cancer Prevention and Control Strategy, 2014).  
Currently in Zimbabwe there is no essential medicines list that incorporates the antineoplastic 
medicines in detail. The 7th Edition of the Essential Medicines List in Zimbabwe has no 
standard detailed approach on how to manage specific types of cancers (National Medicines 
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Therapeutics Advisory Committee, 2015). This lack of standard therapy leads to variability in 
treatment approaches. 
There is a high possibility that with the current economic crunch, most medicines are beyond 
the reach of many, as the majority of people are living below the poverty datum line which was 
USD 596 for a family of five people, as of August 2018 (ZIMSTATS, 2018). With an incidence 
rate of almost 5000 per year, the current cancer treatment and palliation services are unable to 
meet the existing demand for services (National Cancer Prevention and Control Strategy, 
2014). According to the National Cancer Control Program for Zimbabwe, some of the 
challenges that were identified included funding constraints which have resulted from cancer 
being low on the funding agenda. According to Mendis et al. (2007), patients with chronic 
diseases such as cardiovascular disease, diabetes, asthma amongst others require a reliable 
supply of affordable medicines. In the absence of such a supply, avoidable mortality and 
morbidity will occur (Mendis et al., 2007).  
The environment in Zimbabwe is currently unregulated when it comes to pricing of medicines, 
which can negatively impact the availability and affordability of essential medicines, 
antineoplastic medicines being amongst them (Gavaza, 2009). The National Cancer Prevention 
strategy indicated that chemotherapy was very expensive and scarce in public institutions. The 
only option for patients was to use out-of-pocket funds to access those medicines (National 
Cancer Prevention and Control Strategy, 2014). Use of out-of-pocket funds results in low 
accessibility as most people in Zimbabwe are currently unemployed and they are living below 
the poverty datum line (ZIMSTATS, 2018). 
The availability of medicines has worsened with the introduction of the bond note, which is a 
surrogate currency that was introduced by the government of Zimbabwe through Statutory 
Instrument S.I. 133 of 2016 (Government of Zimbabwe, 2016). The bond note is supposed to 
be at par with the United States Dollar (USD), which is the official currency in Zimbabwe. 
However there has been unavailability of the USD to allocate to pharmaceutical companies for 
importation of essential medicines. This has negatively impacted the availability of medicines 
(The Standard Newspaper, 2018). An unofficial exchange rate now exists between the USD 
and the bond notes. This means that the general public will access medicines at an inflated 
unofficial price. 
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1.1.1 Rationale for study  
According to the National Cancer Prevention and Control Strategy (NCPCS), there is a need 
for population-wide, integrated and cohesive approach to cancer that encompasses prevention, 
screening, diagnosis, treatment and support, palliative and rehabilitative care (National Cancer 
Strategy, 2014). Hence a study that assesses the price, accessibility and availability of 
antineoplastic medicines is warranted as it would indicate the economic burden and 
accessibility issues which may be used to guide policy implementation. The study will give a 
quantifiable number that indicates the affordability of antineoplastic medicines, which would 
be of paramount importance for future planning.  
According to the WHO/HAI on MDGs, little data was available on the mark-ups applied to the 
cost of production of medicines as they move through the supply and distribution chains (World 
Health Organisation, 2008). There is a need for studies that would show the current mark-up 
prices and pricing structures of antineoplastic medicines and how these affect accessibility and 
availability. The NCPCS document stated that there had not been reliable or consistent 
documentation of most elements of cancer treatment in Zimbabwe (National Cancer Strategy, 
2014).  
The government has continued to blame the players in the pharmaceutical sector for selling 
medicines in foreign currency at the expense of the patients (The Standard, 2018). This has 
been worsened by the need to source the United States Dollars by the pharmaceutical players 
to support the private health care demand of medicines (The Standard Newspaper, 2018). The 
study will explore the issues affecting the supply chain and the mark-ups and comparison of 
the selling price to the global market through the median price ratios. 
Zimbabwe as a country has been relying on the importation of antineoplastic medicines from 
countries like India, South Africa and other European countries (Medicines Control Authority 
of Zimbabwe, 2018). There has been rationing in the allocation of foreign currency to 
wholesalers for importation of essential medicines from foreign manufacturers who also 
manufacture antineoplastic medicines. The failure by local wholesalers to import medicines 
has resulted in shortages of essential medicines. However, the extent of this shortage is 
unknown. Hence the need to do a study that can detail the reduction in the importation of 
registered products and how this has impacted price and affordability on individuals who now 
have to rely on special importation through the ‘Section 75’ process of the Medicines and 
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Allied Substances Control Act that provides for importation of unregistered medicines by retail 
pharmacies in Zimbabwe (Medicines Control Authority of Zimbabwe, 2018). 
1.1.2 Definition of terminology 
 Medicines accessibility - having medicines continuously available and affordable at 
public or private health facilities or medicines outlets that are within one hour’s walk 
from the homes of the population (WHO, 2018). 
 Essential medicines- are medicines that satisfy the priority health care need of the 
population (WHO, 2005) 
 Affordability -the number of days’ wages for the lowest paid government worker. The 
affordability is then expressed as the number of day’s wages to buy a course of the 
medicine in a month (WHO, 2018) 
To facilitate international comparisons, medicine prices found during the survey are expressed 
as ratios relative to a standard set of international reference prices, known as the median price 
ratio (MPR). The ratio is an expression of how much greater or less the median local medicine 
price is than the international reference price, e.g. an MPR of 2 would mean that the local 
medicine price is twice the international reference price (WHO/HAI, 2008) 
1.1.3 Antineoplastic medicines registration status in Zimbabwe 
The Medicines Control Authority of Zimbabwe (MCAZ) registers, licenses and/or controls 
manufacture, wholesaling, dispensing and importation of all medicines. The government 
institutions import their medicines through the government wholesaler which is the National 
Pharmaceutical Company, whilst the private institutions rely mostly on the approved 
wholesalers in Zimbabwe. Of the seven (7) manufacturing facilities in Zimbabwe, none 
manufacture antineoplastic medicines (MCAZ, 2018). The country relies mainly on generic 
imports from other countries. The government has also put in place through the Medicines and 
Allied Substances Control Act, a special importation called ‘Section 75’, which provides for 
the bulk importation of unregistered essential medicines (MCAZ, 2018). 
1.2 Research Questions 
1.2.1 What are the prices of antineoplastic medicines in Zimbabwe? 
1.2.2 What are the percentage mark-ups of antineoplastic medicines in Zimbabwe’s private 
and public sector? 
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1.2.3 What is the percentage availability of antineoplastic medicines in the public and private 
sectors? 
1.2.4 Are antineoplastic medicines affordable to the general public in Zimbabwe? 
 
1.3 Aims & Objectives 
1.3.1 Aims 
The aim of this research is to determine the price, availability and affordability of antineoplastic 
medicines in Harare’s public and private health institutions in order to guide policy formulation 
that can aid availability and accessibility of antineoplastic medicines. 
 
1.3.2 Objectives 
The objectives of the study are as follows: 
(i) To determine the price of antineoplastic medicines in Harare’s public and private 
health institutions. 
(ii) To determine the percentage availability of antineoplastic medicines. 
(iii) To determine the affordability of antineoplastic medicines. 
(iv) To determine if there are variations in availability, acquisition price and 
affordability between the public and private sectors. 
(v) To determine the price mark-ups of the antineoplastic medicine. 
(vi) To determine the median price ratio by comparing the prices of the antineoplastic 
medicines in Harare against the current International Reference Prices 
1.4 Significance and novelty of work 
The findings of the study have a bearing on a number of government policies such as the 
registration status for the antineoplastic medicines, lobbying for a cancer levy and subsidised 
importation of antineoplastic medicines. The identified price issues like price and mark-ups 
can be used to lobby for such policies as price controls and fixed mark-ups. The National 
Cancer Preventative Control Strategy, lobbied for studies that can result in greater 
understanding of the availability and affordability of antineoplastic medicines. This study will 
contribute to that understanding. 
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According to the study by the WHO, essential medicines that satisfy the priority health care 
needs of the population are the backbone of health care and well-being of individuals. Access 
to essential medicines is a fundamental right (WHO, 2004). There has been significant blame 
shift in the pharmaceutical industry, with the retailers being accused of profiteering. A study 
of this nature will demystify some of these beliefs and facilitate ease of dialogue amongst all 
the players in the pharmaceutical industry (The Standard, 2018). The study will also 
demonstrate the probable challenges that cancer patients have been facing when it comes to 
accessing medicines. 
The median price ratios will also demonstrate the financial challenges that are faced by the 
local importers. There is a need for the government to capacitate the local industry so that there 
is a reduction on importation of antineoplastic medicines. This is only feasible if there is 
evidence based information that demonstrates the availability and price issues surrounding the 
antineoplastic medicines. 
1.5 Research methodology 
1.5.1 Study design 
Study type: Quantitative cross-sectional descriptive survey. 
1.5.1.1 Study setting 
The study was conducted in Harare the capital city of Zimbabwe and the surrounding small 
towns. Harare has a nearby town called Chitungwiza which is 25km away from the Central 
Business District.  
1.5.1.2 Study sample 
The government distribution channels of medicines uses the ‘Vital Essential Necessary’ system 
whereby the public institutions are divided into referral health institutions and primary health 
care centres (National Medicines and Therapeutics Advisory Committee, 2015). The primary 
health institutions are for management of minor ailments and chronic conditions routine 
monitoring, whilst they refer to the referral hospitals. All the hospital were considered for the 
study because of their small number. These were: 
(i) Chitungwiza General Hospital 
(ii) Harare Central Hospital 
(iii) Parirenyatwa Group of Hospitals  
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The Medicines Control Authority of Zimbabwe had 250 pharmacies licensed in the area of 
interest at the time of the study. 
1.5.1.3 Sample Size 
A statistical software was used to calculate the sample size of the pharmacies and the public 
health institutions. The sample size calculator is found on 
www.surveysystem.com/sscalc.htm#two 
  
Sample size for the private pharmacies 
 Confidence level 95% 
 Confidence Interval 5 
 Population 250 
 Sample size 150 
 
 Sample size for the public institutions 
Confidence level 95% 
Confidence Interval 5 
Population 3 
Sample size 3 
1.5.1.4 Sampling 
Multi-stage random sampling was used to sample 150 of the 250 pharmacies in the areas of 
interest. The Medicines Control Authority of Zimbabwe’s premises database was used for 
sampling purposes (MCAZ, 2018). All the licensed pharmacies in Harare were extracted from 
the database and then stratified into those from high density areas and those from low density 
areas. A systematic random sampling approach was then used on the strata were those even 
number pharmacies on the strata were chosen. Convenience sampling was used on the 
government’s referral hospitals. Stratification ensured that the health institutions were as 
representative of the population as is possible and eliminate the location bias. Convenience 
sampling has the advantages of being cheap and in most instances more feasible to the setting 
(Black, 1999). 
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1.5.1.5 Recruitment approval process. 
Letters were written to seek approval from the following departments: 
(i) Director Health Services Chitungwiza for the Municipality owned institutions. 
(ii) Clinical Directors Harare, Parirenyatwa and Harare Hospitals. 
(iii) For the pharmacies, authorisation was sort from each facility’s directors before study 
could be conducted. 
1.5.1.6 Inclusion criteria for the antineoplastic medicines 
 Antineoplastic medicines that have been issued a registration certificate in Zimbabwe. 
 Antineoplastic medicines that have been imported into the country through the ‘section 
75’ process in the year 2018.  
 
1.5.1.7 Exclusion criteria for the antineoplastic medicines 
 Antineoplastic medicines that have been registered and are on the MCAZ drug register 
but have not been imported into the country in the past year. 
 
1.5.1.8 Data Collection Tool/Methodology 
A data collection form-based cross sectional survey was conducted in public and private 
medicine outlets.  A pre-structured data collection form was used (WHO, 2005). The data form 
was administered by the investigator as a hard copy in 3 (three) public institutions and 150 
private health institutions in Harare and Chitungwiza from July to September 2018. The 
pharmacy supervisors provided the data from their dispensing software and records. This data 
was inclusive of the dispensing fees. 
The survey tool focused on the following areas: 
 Type of institution from which data was collected. 
 Medicine generic name, dosage form, strength. 
 Manufacturer. 
 Availability at the institution. 
  Price of the medicine (Procurement price). 
 Selling price of the medicine. 
 Mark-ups of the medicine (Selling price - Aquisition price). 
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 Affordability (Calculated as the number of days’ wage of the least paid government 
worker which was pegged at USD296 (Zimbabwe National Statistics Agency, 2018). 
The affordability of the medicines was calculated based on the medicine required for a 
month’s treatment of various type of cancers as stipulated in the British National 
Formulary and the digital prescribers’ registry (Prescribers Registry, 2018). 
1.5.2 Data Analysis 
Availability 
A ratio scale variable, availability, was calculated as the number of institutions that had the 
medicine on the day of the study as a percentage of the total number of institutions that were 
visited. Availability in the public institutions was compared against availability in private 
institutions. Descriptive measures like percentages and means were calculated. 
Affordability 
Affordability was calculated from the minimum government wage/salary of USD 296. The 
days’ wages were calculated using the unit antineoplastic price i.e the price of unit tablet or 
vial. The monthly or cycle amount of an antineoplastic medicine was considered using the 
standard prescribing doses for the medicines i.e $296 divided by 30 days = 9.86 day wage. This 
then was then used to calculate the number of wage days to acquire the antineoplastic medicine 
(Alefan, 2018).  
Average cost price 
A ratio scale variable, average cost price of the medicine was calculated by finding the average 
sample price for a medicine on those institution that had the medicine on the date of survey 
expressed in USD. Descriptive statistics range, median, mode and mean were calculated. 
Median price ratio 
A ratio scale variable median price ratio was calculated for all the medicines using the 
following equation: 
𝑚𝑒𝑑𝑖𝑎𝑛 𝑙𝑜𝑐𝑎𝑙 𝑢𝑛𝑖𝑡 𝑝𝑟𝑖𝑐𝑒
𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑢𝑛𝑖𝑡 𝑝𝑟𝑖𝑐𝑒
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The WHO International Medical Price list was used for the international reference unit price 
(WHO/Management Science Health, 2015). Median price ratios were calculated for twenty 
(22) of the twenty nine (29) medicines that had been sampled in the population. The inclusion 
criteria for these medicines was an availability of an international reference unit price in 
WHO’s reference unit price list.  
Table 4: List of medicines and their international reference price 
Product Description International 
Reference Price 
in USD 
Price per unit 
Letrozole 2.5mg tablets 0.4179 price per tablet 
Rituximab 100mg injection 13.6721 price/ml 
Tamoxifen 20mg tablets 0.1243 price per tablet 
Oxaliplatin 50mg injection 28.8821 price per vial 
Oxaliplatin 100mg injection 74.7676 price per vial 
Paclitaxel 100mg injection  11.048 price per vial 
Paclitaxel 30mg injection 0.8754 price per ml 
Carboplatin 450mg injection 40.3245 price per vial 
Carboplatin 150mg injection 16.0053 price per vial 
Cisplatin 0.5mg injection 0.515 price per ml 
Vincristine 1mg/ml injection 2.5416 price per vial 
Vinblastine 10mg/10ml injection 4.9762 price per vial 
Vinorelbin 10mg/ml injection 21.965 price per vial 
Imatinib 400mg tablets 25.2098 price per tablet 
Methotrexate 2.5mg tablets 0.1573 price per tablet 
Methotrexate25mg/5ml injection 2.6258 price per vial 
Fluoro-uracil 50mg injection 0.2048 price per ml 
Anastrazole 1mg tablets 0.5271 price per tablet 
Bicalutamide 50mg tablets 0.2343 price per tablet 
Doxorubicin 50mg injection 5.4059 price per vial 
cyclophosphamide 500mg injection 8.16 price per vial 
Docetaxel 80mg injection 17.514 price per vial 
 
Price mark-ups 
An average mark-up per facility was calculated and then an average sample mark-up price was 
calculated. Descriptive statistics that were calculated included the mean, mode and median 
mark-ups. 
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Study sample 
A total of one hundred and sixty (160) data sheets were distributed in private pharmacies, of 
these one hundred and fifty (150) pharmacies responded. Statistical inferences were made from 
these.    
This data was transcribed to Microsoft Excel ®. Statistical analysis such as measures of central 
tendency and measure of dispersion were calculated from this data. 
1.5.2.1 Statistical Analysis 
The data was subsequently exported to and analysed using International Business Machines 
(IBM)’s Statistical Package of the Social Sciences (SPSS) ®, version 23. 
1.5.2.2 Data Cleaning 
For accuracy of transcription, a second person checked the numerical entries for every data 
sheet to verify the correctness of the data. 
1.5.2.3 Data Management 
To protect the identity of the pharmacy respondents and to eliminate bias, pharmacy codes 
were used. The data sheets were stored on a password protected computer and backed-up on a 
password protected hard drive and a copy was stored on the Google drive ®. 
1.5.2.4 Pilot Study 
The data collection tool was validated by a pilot study that involved 15 pharmacies. The number 
was calculated as 10% of the proposed samples. Convenience sampling was used for the pilot 
study sample. 
1.5.2.5 Ethical Approval 
Ethical approval for the study was obtained from the Biomedical Research Ethics Committee 
of the University of KwaZulu-Natal (BE 644/17) - (Annexure 1), as well as from the Medical 
and Research Council of Zimbabwe (MRCZ/B/1524) - (Annexure 2). 
 
 
12 
 
 
1.6 Conclusions 
The introductory chapter looked at the current situation of the problem in Zimbabwe. It also 
explained the micro and macro-economic issues surrounding the health sector. The chapter 
identified the policy issues in Zimbabwe. The chapter introduced the key concepts of the study 
which are accessibility, availability and affordability of antineoplastic medicines. The chapter 
looked at the significance of the study, the research aims and objectives and explored the 
general methodology of the study. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Introduction 
The previous chapter was an introduction to the area of study. This chapter explores the 
information available in the literature for the researcher to get an understanding of the price, 
availability and affordability of antineoplastic medicines from a theoretical perspective. This 
chapter additionally looks at the WHO/HAI method and explores studies done in resource 
limited settings to see the price, availability and the affordability of antineoplastic medicines. 
2.1.2 Cross sectional surveys 
Cross sectional studies measure the prevalence of health outcomes or determinants of health in 
a population at a point in time. For success and credibility of the study there is a need for early 
planning. This is achieved by being able to translate the interest of the study to precisely 
formulated study objectives, choosing the correct sample size, suitable sampling methods, 
response rates and effective parameter analysis (Coggon D et al., 2003).  
The study used a cross sectional study approach (Sedgwick, 2014). This has a number of 
advantages, as follows: 
(i) Ability to rapidly generate data and infer on some health related events for policy 
makers or for generating hypotheses on the topic or for further research. 
(ii) Cross sectional studies are easy to conduct and affordable as compared to other 
forms of research where there is need of follow-up of participants. 
(iii) There is good control of the variable under study because of the one point 
measurement approach. 
(iv) It offers complete data as all variables are measured and data collected at once. 
(v) Data collected by cross sectional studies can be used for additional secondary 
analysis. 
(vi) It allows researchers to study multiple outcomes and exposures at once. 
(vii) There is no loss to follow up as data is collected as participants are interviewed only 
once. 
(viii) With the advent of new technology analysis of cross sectional survey data is easy 
and descriptive statistical parameters can be easily calculated. 
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Cross sectional studies have a number of disadvantages: 
(i) Study is ineffective if it is non-representative of the entire population. 
(ii) It requires a large sample for the data to be correct. 
(iii) Non responsiveness can result in bias of results. 
(iv) It is often associated with the temporal confusion bias called Protopathic bias. 
(v) It does not establish causal relationship between variables. 
(vi) Most surveys lacks desired number of participants for study to be statistically 
significant. In some instances it is inevitable to realise that the participants’ numbers 
does not even permit the achievement of the study’s primary objective. Also non 
responders to a survey maybe atypical representing a subgroup of the population 
with vital inferences to the study (Coggon D et al., 2003). 
2.1.1 Price and availability surveys 
Many surveys have been done to assess the price and availability of medicines in different 
jurisdictions using cross sectional surveys. These surveys collected both qualitative and 
quantitative data that has been used to for policy formulation and implantation. Such studies 
included the study by Marume, 2015, Mhlanga and Suleman, 2014 and Maponga et al., 2009. 
These and many studies were based on the WHO/HAI medicines survey approach. This is a 
self-administered questionnaire based study with an advantage of response standardisation 
(Coggon D et al., 2003). 
2.1.2 The WHO/HAI Project 
The WHO/HAI Project on medicine prices and availability was adopted for this study. This is 
a project that was developed after it was noted that there was a need for increased access to 
medicines as part of the fight against poverty (WHO/HAI, 2008). Also there were few studies 
that had been done in developing countries to measure medicine prices and make international 
comparisons. The absence of a standard methodology to assess medicine availability and 
affordability was seen as a stumbling block. In 2001 the WHO/HAI Project in medicines prices 
and availability was introduced. The main objective was to develop a reliable methodology for 
collecting and analysing medicine price, availability and affordability data. By the end of 2007, 
over 50 surveys had been undertaken worldwide (WHO/HAI, 2008). The results of these 
studies are as below: 
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(i) Medicine prices are high, especially in the private sector (up to 80 times the 
International Reference Price) (WHO/HAI, 2008). 
(ii) Availability was particularly low in the public sector (WHO/HAI, 2008). 
(iii) Treatment was often unaffordable e.g. requiring over 15 days’ wage to purchase 
(WHO/HAI, 2008). 
(iv) Mark-ups in the distribution chain were excessive (WHO/HAI, 2008). 
(v) Numerous taxes and duties were being applied to medicines (WHO/HAI, 2008). 
2.1.3 Medicine price, availability and affordability studies 
Maponga, et al., conducted a cross sectional study entitled, ‘The price people pay for medicines 
in Zimbabwe’ (Maponga et al., 2009). The study concluded that medicine prices in Zimbabwe 
were high. A scenario that would compromise affordability and accessibility to medicines 
especially by the poor. Urgent steps were needed to reduce the level and effect of the high 
prices on the population, especially the poor. The study revealed   that innovator brands in the 
private sector were priced 10 times the International References Prices (IRP) and more than 
three times the price of generic medicines. 
Mendis conducted a study on the availability and affordability of selected essential medicines 
for chronic diseases in six low-and-middle income countries (Mendis, 2007). He conducted a 
survey of the availability and price of thirty two (32) medicines in a representative sample of 
public and private medicine outlets in four geographical areas. He found out that generally total 
availability of medicines in the public sector was considerably lower in all the countries. From 
the research he concluded that context specific policies were required to improve access to 
essential medicines. He also recommended that prices could be reduced by improving 
purchasing efficiency, eliminating taxes and regulating mark-ups (Mendis, 2007). These are 
important recommendations especially the mark-up regulations, as currently in Zimbabwe 
there is no regulation of mark-ups on medicines. 
A study was conducted by (Sado and Sufa, 2016) on availability and affordability of essential 
medicines for children in the western part of Ethiopia using the WHO and HAI tools to measure 
availability, affordability, and prices of essential medicines. They expressed availability as a 
percentage of drug outlets per sector that stocked surveyed medicines on the date of data 
collection. From the study, percentage availability of essential medicines in the public sector 
was 4% and 42.8% in private sector. Lowest priced medicines were sold at 1.18 and 1.54 times 
their International Reference Prices in the public and private sectors respectively. Medicines 
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were unaffordable as they costed a day or more day’s wages for the lowest paid government 
unskilled worker. They concluded that further studies on a large scale were critical to identify 
acute areas for policy interventions such as price and or supply (Sado and Sufa , 2016). 
 A study in Delhi entitled, ‘Where are we now: assessing the price, availability and affordability 
of essential medicines in Delhi as India plans for free medicines for all’ by Kotwani  was 
conducted under the background that inequitable access to medicines was a major weakness in 
the Indian health care system. Baseline data was needed to develop effective public health 
policy and provide equitable access to essential medicines using the standardised WHO/HAI 
methodology. Data on price and availability of medicines was collected from private retail and 
chain pharmacies of a leading corporate house. Prices were compared to an international 
reference price (expressed as median price ratio-MPR). The results of the study indicated that 
the procurement price of surveyed medicines were 0.53-0.82 times the IRP. The overall mean 
availability of surveyed medicines in public facilities was 41.4%. From their study it was 
evident that the majority of India’s population could not afford the prices of the essential 
medicines. They concluded that the availability was very poor in public sector facilities and 
was better in private retail pharmacies but affordability remained a big challenge for a majority 
of the population (Kotwani, 2013). 
A study was conducted by (Babar et al., 2007) in Malaysia entitled, Affordability, and Price 
components: Implications for Access to Drugs in Malaysia, in a background that the health 
care system was facing challenges with increasing medicine costs. The study was conducted to 
evaluate the medicines prices, availability, affordability and the structure of price components. 
The study was conducted in 20 public hospitals, 32 private sector pharmacies and 20 dispensing 
doctors’ clinics. Medicine prices were compared with IRPs. In private pharmacies, innovator 
brands (IB) were 16 times higher than the IRPs. They concluded that in the private sector there 
was a very low median availability of 25%. A low availability of medicines on the National 
Essential Drug list and the drug formulary were found in all sectors. This is the issue with 
anticancer medicines here in Zimbabwe. Also on the price components, add-on costs had a 
substantial impact on medicine prices. 
A study by Mhlanga and Suleman in Swaziland determined the prices, availability and 
affordability of medicines along the supply chain. They used the WHO/HAI standardised 
methodology. From the study the mean availability of essential medicines was 68% in the 
public sector. The total cumulative mark-ups for individual medicines ranged from 190.99%-
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440.27%. The largest contributor to add-on cost was the retail mark-up which ranged from 31-
53%. From the study they concluded that policy measures such as price capping could increase 
availability of drugs. This could be the case with the Zimbabwean system where there is no 
price control.  
A study conducted by Yohana on the availability and affordability of anticancer medicines in 
Dar Es Salaam, Tanzania, in the background where there was little documented information 
regarding the availability and affordability of antineoplastic medicines at the patient level. 
From the cross sectional study conducted on outpatients attending the ORCI clinic, they 
concluded that the availability of antineoplastic medicines was inadequate. Also the prices of 
the medicines in the private pharmacies were high and most of the patients were not on medical 
aid (Yohana, 2010). 
According to a paper on Millennium Development Goals (WHO, 2014) , several countries have 
made substantial progress towards increasing access to essential medicines, but access to 
essential medicines is still not adequate in developing countries. According to the paper, the 
availability of medicines in the public sector,  was only one third whilst in the private sector 
was two thirds and the prices that people paid for the lowest priced generic medicines varied 
from 2.5 times to 6.5 times International Reference Prices in the public and private sectors 
respectively. The millennium development goal target 8.E, which states that in cooperation 
with pharmaceutical companies, governments should be able to provide access to affordable 
essential drugs in developing countries. The proposed indicator was the proportion of the 
population with access to affordable essential medicines on a sustainable basis. In the 27 
countries in which data was available, average public sector availability of essential drugs was 
34.9%. The paper also indicated that low availability of medicines in the public sector could 
be attributed to insufficient funds. The paper also indicated that even though the national 
government procurement prices are usually close to or below the international prices, patients 
paid more owing to mark-ups in the supply chain (WHO, 2014). 
Taxes and duties were identified as other contributors to add-on costs in the supply chain. They 
proposed that medicine prices could be reduced by eliminating duties and taxes on medicines. 
This already is the case here in Zimbabwe, were importers of antineoplastic medicines get tax 
exemption when they apply for it through the Ministry of Health. However, even though there 
is this tax exemption, there is a likelihood that the medicines are still being sold at prices that 
are above the International Reference Prices (WHO, 2014). 
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According to the Global Health Observatory (GHO) data, in low and middle income countries, 
prices of selected lowest priced generics can be more than twice IRPs. Cases in point were 
Congo, Phillipines and Moldova public sectors were patient prices in the public sector were 
over 400% higher than the International Reference Prices. In the private sector the price of 
generics ranged from 32% to 2700% of the International Reference Price (WHO, 2018). 
2.1.3 International reference price and median price ratios 
Medicine prices are expressed as ratios relative to a standard set of reference prices. These are 
listed in the International Medicines Price Indicator guide (WHO/ Management Science Health, 
2015). Median price ratio is calculated for medicines using the following equation: 
𝑚𝑒𝑑𝑖𝑎𝑛 𝑙𝑜𝑐𝑎𝑙 𝑢𝑛𝑖𝑡 𝑝𝑟𝑖𝑐𝑒
𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑢𝑛𝑖𝑡 𝑝𝑟𝑖𝑐𝑒
 
Median price ratios have been used in studies to compare the price of medicines in specific 
jurisdictions to international prices. Jason Shaffrin stated that, IRP is a system whereby a 
country states that they will pay no more than the price paid by another country or a basket of 
countries. In theory, countries could also regulate drug prices by saying that they would not 
pay more than X% of country A’s price or X% of the reference basket of country A, B and C 
(Shaffrin J, 2015). 
2.1.4 Antineoplastic medicines registration, accessibility and oncology care in 
Zimbabwe 
According to the publication by the Zimbabwe National Cancer Registry, the total incidences 
of new cancer cases recorded in Zimbabwe in 2015 was 7 165, comprising 3 041 (42.4%) males 
and 4 124 (57.6%) females. In Harare City a total of 2 518 malignant tumors were registered 
in 2015. These comprised 1 179 (46.8%) males and 1 339 (53.2%) females (Zimbabwe National 
Cancer Registry, 2015). 
The most frequently occurring cancers among Zimbabweans of all races in 2015 were cervix 
uteri (19%), prostate (9%), breast (7%), Kaposi sarcoma (KS) (7%), non-melanoma skin cancer 
(NMSC) (6%), non-Hodgkin lymphoma (NHL) (6%), esophagus (5%), colo-rectal (4%) and 
stomach (3%). The other cancers accounted for 34% of the registered cancers (Zimbabwe 
National Cancer Registry, 2015). 
There are no antineoplastic medicines readily manufactured in Zimbabwe. Zimbabwe depends 
on importation of finished pharmaceutical products from India and Europe (MCAZ, 2018). 
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According to the Ministry of Health and Childcare, only one public facility in Harare, 
Parirenyatwa Hospital provides oncology care. Patients also heavily rely on the private sector 
for access to antineoplastic medicines.  
2.1.5 Areas of agreement of background studies 
Most of the studies that were incorporated into the literature review used the WHO/HAI 
methodology. The main objectives in the studies sought to determine the accessibility and 
availability of essential medicines.  
Most of the studies agreed that the essential medicines were unavailable in the public sector 
and also that the medicines were highly priced in most of the private pharmacies. 
Most of the studies concluded that there was a need of policy changes to ensure that there was 
some form of price regulation and policies that favours availability of medicines to the general 
public.  
2.1.6 Areas of disagreement of background studies 
The study in Sri Lanka was the only one that showed, that essential medicines were fairly 
available in public institutions (Dabare et al, 2014) 
2.1.7 Recommendations from reviewed studies  
The paper on the millennium development goals, recommended that there was need for further 
support for chronic, non-communicable diseases such as cancer. They recommended that tax 
and duty reduction or exemptions on medicines were pivotal in the increase of access to 
essential medicines (WHO, 2014). 
It was also recommended that generally there was a need to use quality assured generic 
medicines that tend to be cheaper than the brand innovators. The National Cancer Prevention 
and Control Strategy in Zimbabwe, said there was a need to have research in priority areas such 
as determining effective ways to improve access to quality cancer health care services to 
decrease the health care costs associated with cancer prevention and cancer treatment. Also 
there was a need to ascertain the feasibility of introducing a cancer levy (ZIMSTATS, 2018). 
The study by Mendis et al., recommended that there was a need for policies that address a 
country’s circumstances to improve accessibility of essential medicines. They also suggested 
that pooling procurement can be an effective policy to improve purchasing efficiency, 
eliminating taxes, regulating mark-up and monitoring the supply chain. Should need arise, 
 
 
20 
 
sometimes there is need to regulate prices through the enforcement of maximum mark-up and 
maximum selling prices (Mendis et al., 2007). 
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CHAPTER 3 FINDINGS 
3.1 Introduction 
This chapter presents the findings from the study and interprets them through a discursive 
section. Conclusions are then made from the interpretations.  
3.2 Findings 
3.2.1 Availability of antineoplastic medicines in private Sector 
Availability was presented as very poorly available i,e ≤10% availability in the institutions that 
were surveyed, poorly available that is 10.1%-20.9% availability in the institutions that were 
surveyed, fairly available 21%-29.9% availability in the institutions surveyed  and better 
available 30-50% availability in the institutions surveyed. This presentation of availability was 
adapted from availability presentation from a study by Alefan et al., 2018.  
Table 5: Availability of antineoplastic medicine in the private sector  
Antineoplastic medicine Availability 
N=150 
Percentage Availability Availability 
Bleomycin 15 IU injection 0 0 very poorly available 
≤10% Darcabazine 200mg injection 0 0 
Imatinib 400mg tablets 1 1% 
Sorafenib 200mg tablets 2 1.3% 
Docetaxel 80mg injection 2 1.3% 
Rituximab 100mg injection 4 2.7% 
Doxorubicin 50mg injection 4 2.7% 
Methotrexate 25mg/5ml injection 6 4% 
Paclitaxel 30mg injection 6 4% 
Aberaterone 250mg tablets 6 4% 
Cyclophosphamide 500mg injection 6 4% 
Carboplatin 450mg injection 8 5.3% 
Vinorelbin 10mg/ml injection 8 5.3% 
Paclitaxel 100mg injection 8 5.3% 
Rituximab 11.7mg/injection 10 7% 
Paclitaxel 300mg injection 12 8% 
Oxaliplatin 50mg injection 12 8% 
Cisplatin 0.5mg injection 14 9.3% 
Oxaliplatin 100mg injection 22 9.8% 
Bevacizumab 25mg injection 16 10.7% poorly available 
10.1%-20.9% Trastuzumab 440mg injection 16 10.7% 
Vinblastine 10mg/10ml injection 16 10.7% 
Carboplatin 150mg injection 20 13.3% 
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Fluoro-uracil 50mg injection 20 13.3% 
Vincristine 1mg/ml injection 30 20% 
Anastrazole 1mg tablets 30  20% 
Letrozole 2.5mg tablets per 30 32 21% fairly available 
21%-29.9% 
 
Goserelin 3.6mg injection 34  26.7% 
Tamoxifen 20mg per  30 tablets 40 26.7% 
Goserelin 10.8mg injection 44 29.3% 
Bicalutamide 50mg tablets 48 32% better available 
30-50% Methotrexate 2.5mg tablets 64  42.7 
 
Nineteen (19) of the thirty two (32) medicines were very poorly available in private sector with 
an availability of less than 10%. Seven (7) of the thirty two (32) medicines were poorly 
available with an availability of greater than 10% but less than 21%. Four (4) of the thirty two 
(32) medicines had a fairly available status. Two (2) of the thirty two (32) medicines namely 
Bicalutamide 50mg tablets and Methotrexate 2.5mg tablets had better availability of between 
30% and 50%. Average percentage availability was 12.38% for the sampled medicines in 
Harare’s private pharmacies. 
3.1.2 Availability in public sector 
Table 6: Availability of antineoplastic medicine in the public sector 
Antineoplastic medicine Availability 
N=1 
Availability 
Methotrexate 25mg/5ml injection Yes Available 
Cyclophosphamide 200mg injection Yes 
Doxorubicin 50mg injection Yes 
Carboplatin 450mg injection Yes 
Paclitaxel 300mg injection Yes 
Vincristine 1mg/ml injection Yes 
Bleomycin 15 IU injection Yes 
Darcabazine 200mg injection Yes 
Docetaxel 80mg injection No Unavailable 
Rituximab 100mg injection No 
Imatinib 400mg tablets No 
Methotrexate 2.5mg tablets No 
Paclitaxel 30mg injection No 
Aberaterone 250mg tablets No   
Vinorelbin 10mg/ml injection No 
Paclitaxel 100mg injection No 
Rituximab 11.7mg/injection No 
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Oxaliplatin 50mg injection No 
Cisplatin 0.5mg injection No 
Oxaliplatin 100mg injection No 
Bevacizumab 25mg injection No 
Sorafenib 200mg tablets No 
Trastuzumab 440mg injection No 
Vinblastine 10mg/10ml injection No 
Carboplatin 150mg injection No 
Fluoro-uracil 50mg injection No 
Anastrazole 1mg tablets No 
Letrozole 2.5mg tablets  No 
Goserelin 3.6mg injection No 
Tamoxifen 20mg tablets No 
Goserelin 10.8mg injection No 
Bicalutamide 50mg tablets No 
 
At Parirenyatwa hospital eight (8) of the thirty two (32) surveyed medicines were available. 
This represented a total of 25% medicines availability. 
3.2.3 Median price ratio for the private sector pharmacies 
Table 4 shows the median price ratio for private sector pharmacies  
Table 7: Median price ratio for the private sector pharmacies 
Product Description International reference 
price in USD 
Local median price in 
USD 
Median price ratio 
Cisplatin 0.5mg injection 0.515 price per ml 0.315 price per ml 0.6 
Oxaliplatin 100mg injection 74.7676 price per vial 64.5 per vial 0.86 
Vinblastine 10mg/10ml injection 4.9762 price per vial 5 per vial 1 
cyclophosphamide 500mg injection 8.16 price per vial 9 price per vial 1.10 
Methotrexate 2.5mg tablets 0.1573 price per tablet 0.18 per tablet 1.14 
Rituximab 100mg injection 13.6721 price/ml 18 price/ml 1.30 
Imatinib 400mg tablets 25.2098 price per tablet 35 price per tablet 1.38 
Oxaliplatin 50mg injection 28.8821 price per vial 41 per vial 1.42 
Vincristine 1mg/ml injection 2.5416 price per vial 4.50 price per vial 1.77 
Carboplatin 450mg injection 40.3245 price per vial 81.10 per vial 2 
Methotrexate25mg/5ml injection 2.6258 price per vial 5.78 per vial 2.20 
Fluoro-uracil 50mg injection 0.2048 price per ml 0.6 per ml 3 
letrozole 2.5mg tablets 0.4179 price per tablet 1.42 price per tablet 3.2 
Doxorubicin 50mg injection 5.4059 price per vial 23 price per vial 4.2 
Paclitaxel 30mg injection 0.8754 price per ml 3.7 per ml 4.22 
Carboplatin 150mg injection 16.0053 price per vial 69.5 per vial 4.34 
Paclitaxel 100mg injection 11.048 price per vial 60 per vial 6 
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Anastrazole 1mg tablets 0.5271 price per tablet 3.56 per tablet 6.7 
Bicalutamide 50mg tablets 0.2343 price per tab 1.7 per tablet 7 
Docetaxel 80mg injection 17.514 price per vial 135 price per vial 7.9 
Vinorelbin 10mg/ml 21.965 price per vial 220 price per vial  10 
Tamoxifen 20mg tablets 0.1243 price per tablet 1.37 per tablet 11 
 
Median price ratios were calculated for twenty-two (22) of the medicines. These medicines 
were included on the basis of having an IRP in the WHO’s International Medicines Guide of 
2015. Fifty percent of the antineoplastic medicines had a price ratio of lower than 4 in the 
private sector. Only two medicines, Tamoxifen 20mg tablets and Vinorelbin 10mg/ml injection 
had MPRs greater than 10 in the private sector. The MPRs for the medicines in private sector 
ranged from 0.60 to 11. 
3.2.4 Median Price Ratio for the public sector pharmacies 
Table 5 shows the median price ratio for public sector pharmacies. 
Table 8: Median price ratio for the public sector pharmacies 
Product Description International Reference 
Price in USD 
Local hospital median 
price in USD 
Median price ratio 
Paclitaxel 300mg/50ml injection 0.8754 per ml 0.636 per ml 0.73 
Cyclophosphamide 200mg injection  4.2070 price per vial 3.80 price per vial 0.90 
Doxorubicin 50mg injection 5.4059 price per vial 5.99 price per vial 1.11 
Carboplatin 450mg injection 40.3245 price per vial 47.50 per vial 1.18 
Vincristine 1mg/ml injection 2.5416 price per vial 3.00 per vial 1.18 
Bleomycin 15U injection 12.3210 price per vial 25.70  per vial 2.09 
Methotrexate25mg/5ml injection 2.6258 price per vial 5.90 per vial 2.25 
 
Median price ratios were calculated for seven (7) of the medicines that were available in the 
public sector. These medicines were included on the basis of having an IRP in the WHO’s 
International Medicines Guide of 2015. Two (2) of the antineoplastic medicines, Paclitaxel 
injection and Cyclophosphamide injection had price ratios of lower than 1 in the public sector, 
meaning they were being sold lower than the IRP. The MPR for the antineoplastic medicines 
ranged from 0.73 to 2.25. 
3.2.5 Affordability  
Affordability was calculated from the minimum government wage/salary of USD 296. The 
days’ wages were calculated using the unit antineoplastic price i.e the price of unit tablet or 
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vial. (WHO, 2018). The monthly or cycle amount of an antineoplastic medicine was considered 
using the standard prescribing doses for the medicines i.e $296 divided by 30 days = 9.86 day 
wage. This then was used to calculate the number of wage days to acquire the antineoplastic 
medicine (Alefan, 2018).  
Table 6 shows affordability in the private sector  
Table 9: Affordability in private sector 
Antineoplastic medicine Median Cost 
Price in USD 
Cost for one 
Month supply in 
USD 
Days wages 
Wage 
 
Affordability 
Cyclophosphamide 500mg injection 9 9 1 day Affordable 
Vincristine 1mg/ml injection 4.50 4.50 1 day 
Sorafenib 200mg tablets 520 35 4 days 
Methotrexate 2.5mg tablets 18 36 4 days 
Tamoxifen 20mg tablets 41 41.00 5 days 
Letrozole 2.5mg tablets  42.5 42.50 5 days 
Vinblastine 10mg/10ml injection 50 50 5 days 
Methotrexate25mg/5ml injection 5.78 50 5 days 
Bicalutamide 50mg tablets 51 51 6 days 
Paclitaxel 300mg injection 69.5 69.50 7 days 
Bevacizumab 25mg injection 94 94 10 days 
Fluoro-uracil 50mg injection 6 108 11 days Slightly 
affordable Anastrazole 1mg tablets 107 107 11 days 
Oxaliplatin 50mg injection 41 123 13 days 
Doxorubicin 50mg injection 23 125 13 days 
Oxaliplatin 100mg injection 64.5 129 13 days 
Cisplatin 0.5mg injection 15.75 157.50 16 days 
Carboplatin 450mg injection 81.10 162.20 17 days 
Paclitaxel 100mg injection 60 190 20 days 
Goserelin 3.6mg injection 203 203 21 days Unaffordable 
Carboplatin 150mg injection 69.5 251.6 26 days 
Goserelin 10.8mg injection 403 403 41 days 
Docetaxel 80mg injection 135 405 41 days 
Vinorelbin 10mg/ml injection 220 440 45 days 
Rituximab 100mg injection 980 980 100 days Highly 
Unaffordable Abiraterone 250mg tablets 1040 1040 106 days 
Imatinib 400mg tablets 1050 1050 106 days 
Rituximab 1400mg/11.7ml injection 1806 1806 184 days 
Trastuzumab 440mg injection 2422 4822 490 days 
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Eleven (11) of the medicines in the private sector were affordable with ten (10) wage days and 
below. Eight (8) of the medicines were slightly affordable with wage days more than 10 days 
but less than twenty (20) days. Five (5) of the medicines had wage days more than twenty (20) 
days. Five (5) of the medicines were highly unaffordable with days’ wages of more than 100 
days to 490 days. From the results the medicines were generally unaffordable on the patient 
part. 
3.2.6 Affordability in the public sector 
Table 7 shows affordability in the public sector.  
Table 10: Affordability in public sector 
Antineoplastic medicine Median Cost 
Price in USD 
Cost for one 
Month supply in 
USD 
Days wages 
Wage of 296 
9.86 per day 
Affordability 
Vincristine 1mg/ml injection 3.00 3.00 1 day Very 
Affordable Cyclophosphamide 200mg injection 3.80 68.40 1 day 
Doxorubicin 50mg injection 5.99 45.32 5 days 
Methotrexate25mg/5ml injection 5.90 47.20 5 days 
Bleomycin 15U injection 25.70 77.10 8 days 
Carboplatin 450mg injection 47.50 95.00 10 days 
Paclitaxel 300mg/50ml injection 31.80 95.40 10 days 
  
Generally antineoplastic medicines were affordable in the public sector as compared to the 
private sector. All the medicines were within 10 days wage. However of the 29 medicines that 
were considered for the study, only seven medicines were available. This means that regardless 
of the low prices at public institutions, the out-of-pocket fees by the patients were still 
considerably high as there was a need to source all the unavailable medicines in the public 
sector.  
3.2.7 Percentage Mark Up 
Average Mark-up in Private Sector Average Mark-up in Public Sector 
51.3% 34.0% 
 
The average percentage mark-up in the private sector was 51.3% and the range was 45% to 
73%. This was derived by calculating the average mark-up, which was the difference in cost 
price of a medicine and the selling price of the medicines found at a facility and then the total 
 
 
27 
 
average for the private. The average mark-up at the private sector was 34% and the range for 
the mark-up was 2% to 64%. 
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CHAPTER 4 DISCUSSION 
4.1 Discussion 
Introduction 
This chapter analyses the results and makes statistical inferences from them. It discusses the 
availability in private and public sector, median price ratio, affordability of antineoplastic 
medicines and percentage mark-ups 
4.1 Availability in the private and public sector 
Medicines were generally more available in the private sector. Thirty (30) of the thirty two (32) 
medicines were available in the private sector pharmacies. This was a percentage availability 
of 98%. Availability was very low in the public sector. Only eight (8) of the thirty two (32) 
medicines were available. This was a percentage availability of 25%. This finding was the same 
with the findings of a study by Kotwani, et al. where the mean availability of essential 
medicines in Dehli was 41.3% in facilities that were under the government control. According 
to the study by Kotwani et al., medicines availability was better in the private retail pharmacies 
as compared to the public facilities. Also the dedication of two hospitals for cancer treatment 
in the whole country had an implication on accessibility of consultation services and 
chemotherapy services. The results also compared with the study by Babar et al. on the study 
entitled, ‘Affordability, and price components: implication to access in Malaysia’. The results 
of the study showed that there was 25% availability of medicines in the public sector and the 
median availability was higher in private institutions at 45%. Unavailability of medicines in 
the public sector in Zimbabwe show a different picture with the other studies that were done 
previously by other researchers. In 2016 in their study on essential medicines, Marume and 
Bangalee, 2016 had essential medicines availability of greater than 80%. This shows a decline 
in availability from previous years in the public sector. However it should be noted that the 
studies mentioned focused on all essential medicines, none focused on antineoplastic medicines 
only.  
The findings in the current study makes it evident that there is spiral decline in availability and 
hence implications on access of antineoplastic medicines and all essential medicines in general. 
4.2 Median price ratio 
The median price ratios in private pharmacies of 0.6 to 11 were calculated in the study, for the 
22 medicines. Medicines price as considerably high in the private sector compared to the public 
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sector which had a median price ratio which ranged from 0.73 to 2.25. The medicines which 
had high median price ratios were those patented products that did not have cheaper alternative 
generics. This means antineoplastic medicines were sold 0.6 to 11 times higher in the private 
retail pharmacies compared to the International Reference Prices.  
Studies done by previous researchers on price and availability of general medicines in 
Zimbabwe, had an average MRP of 1.5 in public sector compared to the 0.73 to 2.25 in the 
current study (Marume and Bangalee, 2016). The MRP of this current study of 0.60 to 11 
resonated with the finding of the Marume and Bangalee study where they had an MRP of 10 
for medicines in the private sector.  This high MRP and low affordability has an implication 
on access of antineoplastic medicines. 
4.3 Affordability 
Generally antineoplastic medicines were affordable in the public sector as compared to the 
private sector. All the medicines were within ten (10) days’ wage compared with the days’ 
wages for private retail pharmacies which ranged from 1 day to 490 days. However of the 32 
medicines that were considered for the study, only nine medicines were available in public 
institutions. This therefore means the more expensive and highly unaffordable medicines that 
were not available might have contributed to the low days’ wages. For those same medicines 
that were available at both the public and private institutions, the differences were very 
minimal. Cases in point were those of methotrexate 25mg/5ml injection which had a median 
price ratio of 5.90 for public institutions and 5.78 for private institutions. There was no 
significant difference between the MRP. The results shows that regardless of the low prices at 
public institutions, the out - of - pocket fees by the patients were still considerably high, as 
there was still a need to source for medicines they can’t access in the public sector. The finding 
of the study was in-line with the technical report on pricing of cancer medicines (WHO, 2019). 
They reported that there has been an in increase in the spending on cancer medicines from 
US$90.9 billion in 2012 to US$133 in 2017. They reported that per capita spending on cancer 
medicines has increased by 2 to 8 fold the overall per capita on health expenditure.  
Eleven (11) of the medicines in the private sector were affordable with ten (10) wage days and 
below. Eight (8) of the medicines were slightly affordable with wage days more than ten (10) 
days but less than 20 days. Five (5) of the medicines had wage days more than 20 days. Five 
(5) of the medicines were highly unaffordable with days wages of more than 100 days to 490 
days. From the results the medicines were generally unaffordable on the patient part.  The 
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findings of the study was contrary to with the findings of Alefan et al., 2018  in which their 
study in Jordan revealed that more of the essential medicines were affordable costing up to 1 
days wage or less.  
4.4 Percentage mark-up 
The average percentage mark-up in the private sector was 51.3% and the range was 45% to 
73%, whilst the average mark-up at the private sector was 34% and the range for the mark-up 
was 2% to 64%. The difference in prices is explained by the differences in the operational 
costs. 
Government needs to capacitate local industry on antineoplastic medicines dossier acquisition 
and manufacturing industry resuscitation so that products are manufactured locally. This 
reduces transport costs which also imparts on the overall price of medicines. This also increases 
competition and hence has the potential to reduce prices and the price burden on the patients. 
4.5 Study strength  
 The study used a worldwide WHO/HAI recognised study methodology (WHO/HAI, 
2008). 
 The study sample was calculated using a 95% confidence level and a 5% confidence 
interval. This means the sample is a good representation of the population. 
 The study used stratification and random sampling for the samples which eliminates 
bias (Black, 1999). 
4.6 Limitations of the study  
 There are no major studies that have been done in Zimbabwe and the region on the price 
and availability of antineoplastic medicines, hence background information was very 
limited.  
 There was low medicines availability in public sector which compromised the median 
price ratio comparison between the private and public sector. 
 Also affordability was calculated on the wage/salary of the least paid government 
worker, this is not indicative enough in an economic environment with a greater than 
60% unemployment rate. It is difficult to translate the affordability to the generally 
unemployed population (ZIMSTATS, 2018).  
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 Not all antineoplastic medicines had IRPs. This resulted in other medicines not being 
considered for MPRs and hence limited the quality of data. 
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CHAPTER 5 CONCLUSION 
The generic medicines policy should be used as the median prices of generic medicines tend to 
be low as compared to the brand medicines. The MRPs of antineoplastic medicines in 
Zimbabwe for both the private and public institutions have shown that the medicines are not 
highly priced compared to the IRP taking into consideration the fact that we are not 
manufacturing any of the antineoplastic medicines. 
Generally availability of antineoplastic medicines amongst other essential medicines was very 
low in the public sector and there were very few institutions that had more than 50% availability 
in private pharmacies. There is a need for government health levy also being used for 
subsidisation of acquisition of oncology medicines. 
These results shows that antineoplastic medicines were highly unaffordable taking into 
consideration the poverty datum line in Zimbabwe and the high unemployment rate. However 
the root cause analysis of the current prices had nothing to do with the mark-up of medicines 
in private and public pharmacies, as mark ups of 30 to 50% were noted during the study. It was 
more on the acquisition costs of the imported medicine in the supply chain. There is need of 
government subsidising the importation of essential medicines and availing foreign currency 
for pharmaceutical wholesalers and importers of medicines. 
From the findings of this study where the price and affordability of antineoplastic medicines 
had an implication on access of medicines to the general public, more studies on availability 
and affordability of medicines need to be done in Zimbabwe to support policy formulation on 
better availability of medicines. More understanding is needed on how issues like out-pocket-
payments impact accessibility. There is need of more research on alternative complementary 
medicines that can positively adjust the quality of life of cancer patients at a lower price. This 
is because the conventional medicines’ low availability and low affordability as was 
demonstrated by this study means a great part of the population in Zimbabwe might not be 
accessing the conventional antineoplastic medicines. 
There is a need for an objective, transparent and feasible price regulation system in the medical 
sector in Zimbabwe. This been warranted by the current unregulated market which might have 
an implication on the price and hence MPRs of medicines. From this study it was also evident 
there is need of prescribed policies that guides acquisition of medicines within government 
institutions and as per set approved IRP in public institutions. 
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Both the private sector and public sector should make us of pooled procurement and cut out 
the middlemen normally the wholesalers whom sometimes might have exclusive 
distributorship rights with manufacturers. There is a need for a review of policies on 
distributorship rights in Zimbabwe to increase access to medicines. There is need of ensuring 
that the applicants of medicines in Zimbabwe are manufacturers rather than distributors. This 
eliminates monopoly and hence increase competition. 
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Abstract 
Background: Few studies have been conducted on price, availability and affordability of 
antineoplastic medicines.  In Zimbabwe, there are currently no government policies on pricing 
and accessibility of antineoplastic medicines in public and private institutions, as is the case 
with HIV/AIDS medicines, antimalarial and anti-tuberculosis medicines. This is despite an 
annual cancer incidence of 7165 in Zimbabwe. Study was conducted on a background of better 
characterization of the cancer disease in the 20th century and advent of newer therapies that 
might be costly and whose therapeutic benefit cannot be supported clinically. 
Aim: To determine the price, availability and affordability of antineoplastic medicines in 
Harare’s public and private institutions. 
Setting: Private and public sector pharmacies in Harare and Chitungwiza, Zimbabwe 
Methods: The study was based on the standardised methodology recommended by the World 
Health Organisation (WHO) and Health Action International (HAI). A cross-sectional survey 
was conducted in public and private medicine outlets for thirty two (29) antineoplastic 
medicines.  A total of 153 facilities were surveyed. These consisted of three (3) Central 
Hospitals and one hundred and fifty (150) private pharmacies. The percentage availability, 
Median Price Ratio (MRP) using International Reference Prices (IRPs), mark-ups, price and 
affordability of antineoplastic medicines were determined.  
Results: The percentage availability of the antineoplastic medicines at the government 
institutions was 28%, whilst the percentage availability of the antineoplastic medicines in the 
private sector ranged from 1.3% to 42.7%. Fifty percent of the twenty-two (22) medicines in 
the private sector had a median price ratio of lower than 4. The median price ratio in the private 
sector ranged from 0.6 to 11. The median price ratio in the public sector ranged from 0.73 to 
2.25. Eleven (11) of the medicines in the private sector were affordable with ten (10) days wage 
and below. Eight of the medicines were slightly affordable with wage days more than 10 days. 
Wage days in private sector ranged from 1 day to 490 days. Affordability of the medicines in 
the public sector ranged from 1 to 10 days wage. The average percentage mark-up was 51.3% 
in the private sector and 34% in the public sector for the medicines that were available. 
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Conclusion 
Medicines were generally more available in the private sector than in the public sector.  
Generally medicines were more affordable in the public sector than in the private sector. The 
average percentage mark-ups for antineoplastic medicines were 51.3% in private pharmacies 
and 34% in the public sector.   
From the study it was evident that medicines in the private sector were sold at higher prices 
than the IRP and hence the price had a negative impact on availability. Medicines were 
generally not very affordable for the greater part of the population. 
Keywords: Affordability, Antineoplastic medicines, Medicines availability, Price  
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Introduction 
One of the Millennium Development Goals (MDGs) acknowledges the need to improve the 
availability of affordable medicines for all people in developing countries (WHO/HAI, 2008). 
This goal has been adopted into goal number 3 on good health well-being of the Sustainable 
Development Goals (United Nations, 2015).1 In Zimbabwe many initiatives have been put in 
place through the Global Fund that mainly looks into three main ‘major’ diseases, that is 
HIV/AIDs, malaria and tuberculosis.2 No major initiatives have been put in place to alleviate 
the burden of cancer treatment and palliative services. 
According to the national cancer strategy of the Ministry of Health and Child Care, Zimbabwe 
has a cancer incidence of approximately 7145 cases per annum. The country’s cancer treatment 
and palliation services are unable to meet the demand for services. The National Cancer control 
program identified low funding as one of the challenges3. The country with a population of 14 
million people has a national poverty datum line of USD590.7 for a family of five people4. The 
majority of Zimbabweans live below the poverty datum line and this has an impact on 
accessibility of antineoplastic medicines.  
According to Mendis et al., patients with chronic diseases require a reliable supply of 
affordable medicines. In the absence of such a supply, avoidable mortality and morbidity will 
increase. There is a need for supply of safe, efficacious and good quality antineoplastic 
medicines for cancer patients to reduce the disease burden in the population. 
Zimbabwe does not regulate medicine prices. This can negatively impact the availability and 
affordability of essential medicines, like antineoplastic medicines.5 In developing countries 
there is a tendency of medicine price inflation, medicine price transparency issues, and 
medicine price uniformity in an unregulated medicines market. In South Africa, the single exit 
price legislation that was introduced has addressed each of these issues by reducing medicine 
price inflation, improving medicine price transparency, and ensuring patients pay the same 
price for medicines irrespective of point of access.6 However the introduction of the SEP has 
not yielded the desired outcomes of reduced medicine inflation and medicine price uniformity 
and there was a need for more research to see if implemented government policies yielded the 
desired outcomes.7 
Studies conducted in Swaziland7, Zimbabwe8 and India9 to assess the cost availability and 
affordability of antineoplastic medicines have showed that generally there is low availability 
of essential medicines in public institutions as compared to private institutions. 
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In Zimbabwe there is currently no essential medicines list that incorporates the antineoplastic 
medicines in detail.9 This brings about variability in palliative care and can result in high out -
of-pocket costs to patients. 
A study was therefore done to explore prices, availability and affordability of antineoplastic 
medicines in Harare’s private and public health institutions.  
Methods 
Study type 
Quantitative cross-sectional survey based on the WHO/HAI method.10 
Study setting and sampling 
The study was conducted in Harare the capital city of Zimbabwe and the surrounding small 
towns and areas. Harare has a nearby town called Chitungwiza which is 25km away from the 
Central Business District. There are 250 private pharmacies and 3 public hospitals in the study 
setting. 
Study sample 
The cross sectional survey was conducted in public and private medicine outlets. A total of one 
hundred fifty three (153) facilities were surveyed. These consisted of three (3) central hospitals 
and one hundred and fifty (150) private pharmacies11. The percentage availability, median price 
ratio using international reference prices (IRPs) mark-ups, price and affordability of 
antineoplastic medicines were determined12.  
Sampling 
Multi-stage random sampling and convenience sampling criteria was used to sample the 150 
pharmacies of the 250 pharmacies in the areas of interest. The Medicines Control Authority of 
Zimbabwe’s premises database was used for sampling purposes11. All the licensed pharmacies 
in Harare were extracted from the database and then stratified into those from high density 
areas and those from low density areas. A systematic random sampling approach was then 
implored on the strata were those even number pharmacies on the strata were chosen. 
Convenience sampling was implored on the government’s referral hospitals because of their 
low number. Stratification ensured that the health institutions were as representative of the 
population as is possible and eliminate the location bias. Convenience and random sampling 
have the advantages of being cheap and in most instances more feasible to the setting.13 
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Selection of targeted antineoplastic medicines 
As shown by table below. Antineoplastic medicines that have been issued a registration 
certificate in Zimbabwe and those that had been imported into the country through the special 
import process for unregistered medicines process in the year 2018 were included into the 
study. The WHO (2015) International Medical Price list was used for the international 
reference prices.14 Median price ratios were calculated for twenty (22) of the thirty (29) 
products that had been sampled in the health institutions.   
Table 1 Table of surveyed medicines 
Antineoplastic medicine Median cost 
price in USD 
Cyclophosphamide 500mg injection 9 
Vincristine 1mg/ml injection 4.50 
Sorafenib 200mg tablets 520 
Methotrexate 2.5mg tablets 18 
Tamoxifen 20mg tablets 41 
Letrozole 2.5mg tablets  42.50 
Vinblastine 10mg/10ml injection 50 
Methotrexate25mg/5ml injection 5.78 
Bicalutamide 50mg tablets 51 
Paclitaxel 300mg injection 69.50 
Bevacizumab 25mg injection 94 
Fluoro-uracil 50mg injection 6 
Anastrazole 1mg tablets 107 
Oxaliplatin 50mg injection 41 
Doxorubicin 50mg injection 23 
Oxaliplatin 100mg injection 64.50 
Cisplatin 0.5mg injection 15.75 
Carboplatin 450mg injection 81.10 
Paclitaxel 100mg injection 60 
Goserelin 3.6mg injection 203 
Carboplatin 150mg injection 69.50 
Goserelin 10.8mg injection 403 
Docetaxel 80mg injection 135 
Vinorelbin 10mg/ml injection 220 
Rituximab 100mg injection 980 
Abiraterone 250mg tablets 1040 
Rituximab 1400mg/11.7ml/injection 1806 
Trastuzumab 440mg injection 2422 
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Data Collection Tool/Methodology 
A data collection form-based cross sectional survey was conducted in public and private 
medicine outlets.  The data form was administered by the investigator as a hard copy in 3 (three) 
public institutions and 150 private health institutions in Harare and Chitungwiza from July to 
September 2018. 
The survey tool focused on the following areas, type of institution from which data was 
collected, medicine generic name, dosage form, strength, manufacturer, availability at the 
institution, cost price of the medicine (procurement price), selling price of the medicine, mark-
ups of the medicine (selling price - cost price). 
Affordability (calculated as the number of days’ wage of the least paid government worker 
which was pegged at USD29615). The affordability of the medicines was calculated based on 
the medicine required for a month’s treatment of various type of cancers as stipulated in the 
British National Formulary and the Digital Prescribers Registry.16 
Average price of the medicine was calculated by finding the average price for the medicine on 
those institutions that had the medicine on the date of survey expressed in USD. Descriptive 
statistics i.e.  range, median, mode and mean were calculated. 
Median price ratio was calculated for all the medicines with an IRP using the following 
equation: 
𝑚𝑒𝑑𝑖𝑎𝑛 𝑙𝑜𝑐𝑎𝑙 𝑢𝑛𝑖𝑡 𝑝𝑟𝑖𝑐𝑒
𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑢𝑛𝑖𝑡 𝑝𝑟𝑖𝑐𝑒
 
 
Statistical Analysis 
The data was subsequently exported to and analysed using International Business Machines 
(IBM)’s Statistical Package of the Social Sciences (SPSS) ®, version 23. With the help of a 
biostatistician, MRPs of the twenty two (22) medicines with IRPs, percentage mark-up, 
percentage availability were calculated. 
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Data Cleaning 
For accuracy of transcription, a second person checked the numerical entries for every data 
sheet to verify the correctness of the data. 
Data Management 
To protect the identity of the pharmacy respondents and to eliminate bias, pharmacy codes 
were used. Whereby instead of the pharmacy names, the code was used. The data sheets were 
stored on a password protected computer and backed-up on a password protected hard drive 
and a copy was stored on the Google drive ®. 
Results 
Availability in Private Sector 
Table 2: Availability of antineoplastic medicine in the private sector  
 
Antineoplastic medicine Availability 
N=150 
Percentage Availability Availability 
Bleomycin 15 IU injection 0 0 very poorly available 
≤10% Darcabazine 200mg injection 0 0 
Imatinib 400mg tablets 1 1% 
Sorafenib 200mg tablets 2 1.3% 
Docetaxel 80mg injection 2 1.3% 
Rituximab 100mg injection 4 2.7% 
Doxorubicin 50mg injection 4 2.7% 
Methotrexate 25mg/5ml injection 6 4% 
Paclitaxel 30mg injection 6 4% 
Aberaterone 250mg tablets 6 4% 
Cyclophosphamide 500mg injection 6 4% 
Carboplatin 450mg injection 8 5.3% 
Vinorelbin 10mg/ml injection 8 5.3% 
Paclitaxel 100mg injection 8 5.3% 
Rituximab 11.7mg/injection 10 7% 
Paclitaxel 300mg injection 12 8% 
Oxaliplatin 50mg injection 12 8% 
Cisplatin 0.5mg injection 14 9.3% 
Oxaliplatin 100mg injection 22 9.8% 
Bevacizumab 25mg injection 16 10.7% poorly available 
10.1%-20.9% Trastuzumab 440mg injection 16 10.7% 
Vinblastine 10mg/10ml injection 16 10.7% 
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Carboplatin 150mg injection 20 13.3% 
Fluoro-uracil 50mg injection 20 13.3% 
Vincristine 1mg/ml injection 30 20% 
Anastrazole 1mg tablets 30  20% 
Letrozole 2.5mg tablets per 30 32 21% fairly available 
21%-29.9% 
 
Goserelin 3.6mg injection 34  26.7% 
Tamoxifen 20mg per  30 tablets 40 26.7% 
Goserelin 10.8mg injection 44 29.3% 
Bicalutamide 50mg tablets 48 32% better available 
30-50% Methotrexate 2.5mg tablets 64  42.7 
 
Sixteen (19) of the thirty two (32) medicines were very poorly available in private sector with 
an availability of less than 10%. Seven (7) of the thirty two (32) medicines were poorly 
available with an availability of greater than 10% but less than 21%. Four (4) of the thirty two 
(32) medicines had a fairly available status. Two (2) of the thirty two (32) medicines namely 
Bicalutamide 50mg tablets and Methotrexate 2.5mg tablets had better availability of between 
30% and 50%. Average percentage availability was 12.38% for the sampled medicines in 
Harare’s private pharmacies. 
Availability in public sector 
Table 3: Availability of antineoplastic medicine in the public sector 
Antineoplastic medicine Availability 
N=1 
Availability 
Methotrexate 25mg/5ml injection Yes Available 
Cyclophosphamide 200mg injection Yes 
Doxorubicin 50mg injection Yes 
Carboplatin 450mg injection Yes 
Paclitaxel 300mg injection Yes 
Vincristine 1mg/ml injection Yes 
Bleomycin 15 IU injection Yes 
Darcabazine 200mg injection Yes 
Docetaxel 80mg injection No Unavailable 
Rituximab 100mg injection No 
Paclitaxel 30mg injection No 
Aberaterone 250mg tablets No   
Methotrexate 2.5mg tablets No 
Vinorelbin 10mg/ml injection No 
Paclitaxel 100mg injection No 
Rituximab 11.7mg/injection No 
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Oxaliplatin 50mg injection No 
Cisplatin 0.5mg injection No 
Oxaliplatin 100mg injection No 
Bevacizumab 25mg injection No 
Sorafenib 200mg tablets No 
Trastuzumab 440mg injection No 
Vinblastine 10mg/10ml injection No 
Carboplatin 150mg injection No 
Fluoro-uracil 50mg injection No 
Anastrazole 1mg tablets No 
Letrozole 2.5mg tablets  No 
Goserelin 3.6mg injection No 
Tamoxifen 20mg tablets No 
Imatinib 400mg tablets No 
Goserelin 10.8mg injection No 
Bicalutamide 50mg tablets No 
 
At Parirenyatwa hospital eight (8) of the thirty two (32) surveyed medicines were available. 
This represented a total of 25% medicines availability. 
Median price ratio for the private sector pharmacies 
Table 4 Median Price ratio for the private sector pharmacies 
Product Description International reference 
price in USD 
Local median price in 
USD 
Median price ratio 
Cisplatin 0.5mg injection 0.515 price per ml 0.315 price per ml 0.6 
Oxaliplatin 100mg injection 74.7676 price per vial 64.5 per vial 0.86 
Vinblastine 10mg/10ml injectrion 4.9762 price per vial 5 per vial 1 
Cyclophosphamide 500mg injection 8.16 price per vial 9 price per vial 1.10 
Methotrexate 2.5mg tablets 0.1573 price per tablet 0.18 per tablet 1.14 
Rituximab 100mg injection 13.6721 price/ml 18 price/ml 1.3 
Imatinib 400mg tablets 25.2098 price per tablet 35 price per tablet 1.38 
Oxaliplatin 50mg injection 28.8821 price per vial 41 per vial 1.42 
Vincristine 1mg/ml injection 2.5416 price per vial 4.50 price per vial 1.77 
Carboplatin 450mg injection 40.3245 price per vial 81.10 per vial 2 
Methotrexate25mg/5ml injection 2.6258 price per vial 5.78 per vial 2.20 
Fluoro-uracil 50mg injection 0.2048 price per ml 0.6 per ml 3 
Letrozole 2.5mg tablets 0.4179 price per tablet 1.42 price per tablet 3.2 
Doxorubicin 50mg injection 5.4059 price per vial 23 price per vial 4.2 
Paclitaxel 30mg injection 0.8754 price per ml 3.7 per ml 4.22 
Carboplatin 150mg injection 16.0053 price per vial 69.5 per vial 4.34 
Paclitaxel 100mg injection 11.048 price per vial 60 per vial 6 
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Anastrazole 1mg tablets 0.5271 price per tablet 3.56 per tablet 6.7 
Bicalutamide 50mg tablets 0.2343 price per tablet 1.7 per tablet 7 
Docetaxel 80mg injection 17.514 price per vial 135 price per vial 7.9 
Vinorelbin 10mg/ml injection 21.965 price per vial 220 price per vial  10 
Tamoxifen 20mg tablets 0.1243 price per tablet 1.37 per tablet 11 
 
Median price ratio were calculated for 22 (twenty) of the medicines. These medicines were 
included on the basis of having an international reference price in the WHO’s international 
medicines guide of 2015. 50% of the antineoplastic medicines had a medicine price ratio of 
lower than four (4) in the private sector. Only two medicines, Vinorelbin 10mg/ml and 
Tamoxifen 20mg   had median price ratio greater than 10 (ten) in the private sector. The median 
price ratio ranged from 0.6 to 11. 
Median price ratio for the public sector pharmacies 
Table 5 Median price ratio for the public sector pharmacies 
Product Description International reference 
price in USD 
Local hospital median 
price in USD 
Median price ratio 
Paclitaxel 300mg/50ml injection 0.8754 per ml 0.636 per ml 0.73 
Cyclophosphamide 200mg injection  4.2070 price per vial 3.80 price per vial 0.90 
Doxorubicin 50mg injection 5.4059 price per vial 5.99 price per vial 1.11 
Carboplatin 450mg injection 40.3245 price per vial 47.50 per vial 1.18 
Vincristine 1mg/ml injection 2.5416 price per vial 3.00 per vial 1.18 
Bleomycin 15U injection 12.3210 price per vial 25.70  per vial 2.09 
Methotrexate 25mg/5ml injection 2.6258 price per vial 5.90 per vial 2.25 
 
Median Price Ratios were calculated for seven (7) of the medicines that were available in public 
sector. These medicines were included on the basis of having an international reference price 
in the WHO’s international medicines guide of 2015. Two (2) of the antineoplastic medicines, 
Paclitaxel 300mg/50ml injection and Cyclophosphamide 200mg injection had median price 
ratio (MRP) of lower than one (1) in the public sector, meaning they were being sold lower 
than the IRP. The MRP ranged from 0.73 to 2.25 in the public sector. 
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Affordability in private sector 
Affordability was calculated from the minimum government wage/salary of USD 296. The 
days’ wages were calculated using the unit antineoplastic price i.e the price of unit tablet or 
vial. (WHO, 2018). The monthly or cycle amount of an antineoplastic medicine was considered 
using the standard prescribing doses for the medicines i.e $296 divided by 30 days = 9.86 day 
Table 6 affordability in private sector 
Antineoplastic medicine Median Cost 
Price in USD 
Cost for one 
Month supply in 
USD 
Days wages 
Wage 
 
Affordability 
Cyclophosphamide 500mg injection 9 9 1 day Affordable 
Vincristine 1mg/ml injection 4.50 4.50 1 day 
Sorafenib 200mg tablets 520 35 4 days 
Methotrexate 2.5mg tablets 18 36 4 days 
Tamoxifen 20mg tablets 41 41.00 5 days 
Letrozole 2.5mg tablets  42.5 42.50 5 days 
Vinblastine 10mg/10ml injection 50 50 5 days 
Methotrexate25mg/5ml injection 5.78 50 5 days 
Bicalutamide 50mg tablets 51 51 6 days 
Paclitaxel 300mg injection 69.5 69.50 7 days 
Bevacizumab 25mg injection 94 94 10 days 
Fluoro-uracil 50mg injection 6 108 11 days Slightly 
affordable Anastrazole 1mg tablets 107 107 11 days 
Oxaliplatin 50mg injection 41 123 13 days 
Doxorubicin 50mg injection 23 125 13 days 
Oxaliplatin 100mg injection 64.5 129 13 days 
Cisplatin 0.5mg injection 15.75 157.50 16 days 
Carboplatin 450mg injection 81.10 162.20 17 days 
Paclitaxel 100mg injection 60 190 20 days 
Goserelin 3.6mg injection 203 203 21 days Unaffordable 
Carboplatin 150mg injection 69.5 251.6 26 days 
Goserelin 10.8mg injection 403 403 41 days 
Docetaxel 80mg injection 135 405 41 days 
Vinorelbin 10mg/ml injection 220 440 45 days 
Rituximab 100mg injection 980 980 100 days Highly 
Unaffordable Abiraterone 250mg tablets 1040 1040 106 days 
Imatinib 400mg tablets 1050 1050 106 days 
Rituximab 1400mg/11.7ml injection 1806 1806 184 days 
Trastuzumab 440mg injection 2422 4822 490 days 
 
Eleven (11) of the medicines in the private sector were affordable with ten (10) wage days and 
below. Eight (8) of the medicines were slightly affordable with wage days more than ten (10) 
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days but less than 20 days. Five (5) of the medicines had wage days more than Twenty (20) 
days. Five (5) of the medicines were highly unaffordable with days’ wages of more than 100 
days to 490 days. From the results the medicines were generally unaffordable on the patient 
part. 
4.1.6 Affordability in the public sector 
Table 7: Affordability in public sector 
Antineoplastic medicine Median Cost 
Price in USD 
Cost for one 
Month supply in 
USD 
Days wages 
Wage of 296 
9.86 per day 
Affordability 
Vincristine 1mg/ml injection 3.00 3.00 1 day Very 
Affordable Cyclophosphamide 200mg injection 3.80 68.40 1 day 
Doxorubicin 50mg injection 5.99 45.32 5 days 
Methotrexate25mg/5ml injection 5.90 47.20 5 days 
Bleomycin 15U injection 25.70 77.10 8 days 
Carboplatin 450mg injection 47.50 95.00 10 days 
Paclitaxel 300mg/50ml injection 31.80 95.40 10 days 
  
Generally antineoplastic medicines were affordable in the public sector as compared to the 
private sector. All the medicines were within 10 days wage. However of the 22 medicines that 
were considered for the study, only nine medicines were available and affordability was 
calculated for 7 of the medicines. This means that regardless of the low prices at public 
institutions, the out of pocket fees by the patients were still considerably high as there was need 
to source for all the unavailable medicines in the public sector.  
Percentage Mark Up 
Average mark up in private sector Average mark up in public sector 
51.3% 34.0% 
 
The average percentage mark-up in private sector was 51.3% and the range was 45% to 73%. 
This was derived by calculating the average mark-up, which was the difference in cost price of 
a medicine and the selling price of the medicines found at a facility and then the total average 
for the private sector was calculated. The average mark-up at the private sector was 34% and 
the range for the mark-up was 2% to 64%. 
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Discussion 
The study looked at price, availability and affordability of antineoplastic medicines in Harare’s 
public and private institutions: Implications for access in a background where there was no 
price regulations in Zimbabwe and general unavailability of medicines. 
The objectives of the study were to understand the price of antineoplastic medicines in 
Zimbabwe. To calculate the affordability, percentage mark-ups and percentage availability of 
antineoplastic medicines in Zimbabwe’s private and public sector pharmacies. The study was 
conducted in a background were there was unavailability of medicines price control policy and 
significant blame of retailers by the government that there have been profiteering. The findings 
from the study will assist policies such as registration status for antineoplastic medicines, 
government policies such as cancer levy and subsidised importation of antineoplastic 
medicines 
The study also demonstrated the challenges that cancer patients faced when it comes to 
accessing medicines, as most of them were living below the poverty datum line and the wage 
days to acquire antineoplastic medicines were very high ranging from 1 to 490 days for them. 
 Medicines were generally more available in the private sector. 94% of the medicines were 
available in the private sector pharmacies Availability was very low in the public sector. This 
finding was in-line with the findings of a study by Kotwani, et al. where the mean availability 
of essential medicines in Dehli was 41.3% in public institutions. According to the study by 
Kotwani et al, medicines availability was better in the private retail pharmacies as compared to 
the public facilities17. The results also compared with the study by Zaheer Ud Din Babar et al18. 
The results of the study showed that there was 25% availability of medicines in the public 
sector and the median availability was higher in private institutions at 45 %. The result shows 
that Zimbabwe as a country still has challenges in availability of antineoplastic medicines in 
the public sector. More has to be done in the supply chain and policies have to be implemented 
to increase availability in public sector. 
The median price ratios in private pharmacies of 0.6 to 11, for the 22 medicines indicated that 
antineoplastic medicines were considerably high in the private sector compared to the private 
sector which had a median price ratio which ranged from 0.73 to 2.25. The medicines which 
had high median price ratios were brand products that did not have cheaper alternative generics. 
This means antineoplastic medicines were sold 0.60 to 11 times higher compared to the 
international reference prices. This result tallied with the finding by Marume and Bangalee, 
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2016 were an MPR of 10 for essential medicines was found in the private sector. More still 
needs to be done to ensure that generics that cost less to the brand medicines are available for 
antineoplastic medicines. This can be achieved by having policies that increase accessibility of 
generic medicines. 
Eleven (11) of the medicines in the private sector were affordable with 10 wage days and 
below. Eight (8) of the medicines were slightly affordable with wage days more than 10 days 
but less than 20 days. Five (5) of the medicines had wage days more than 20 days. Four (4) of 
the medicines were highly unaffordable with days wages of more than 100 days to 490 days. 
From the results the medicines were generally unaffordable. The unaffordability of the 
antineoplastic medicines results in a decrement in the quality of life of cancer patients. 
Government subsidise could be alternative measures to bridge the gap in affordability.  
Generally antineoplastic medicines were affordable in the public sector as compared to the 
private sector. All the medicines were within ten (10) days’ wage compared with the days’ 
wages for private retail pharmacies which ranged from 1 day to 490 days. However of the 22 
medicines that were considered for the study, only six medicines were available in public 
institutions. This therefore means the more expensive and highly unaffordable medicines that 
were not available might have contributed to the low days’ wages. For those same medicines 
that were available at both the public and private institutions, the differences were very 
minimal. Cases in points were those of methotrexate 25mg/5ml injection which had a median 
price ratio of 5.90 for public institutions and 5.78 for private institutions. There was no 
significant difference between the MRP. The results shows that regardless of the low prices at 
public institutions, the out-of-pocket fees by the patients were still considerably high, as there 
was still a need to source for medicines they can’t access in the public sector.  
The average percentage mark-up in private sector was 51.3% and the range was 45% to 73%. 
Whilst the average mark-up at the public sector was 34% and the range for the mark-up was 
2% to 64%. The difference in prices is explained by the differences in the operational costs. 
The private institutions have to cater for their overhead expenses from the profit margins from 
the sale of medicines. This is not the case with the public sector were some of the operational 
costs are subsidised and some of the medicines are donated by various donors. 
Strengths and limitations of the study 
The study used a worldwide WHO/HAI recognised study methodology.10 The study sample 
was sufficient for a survey as it surpasses the 50 samples which is minimum for a cross 
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sectional survey. The study used stratification and random sampling for the samples to 
eliminate bias. The limitations of the study were that no major studies have been done in 
Zimbabwe and the region on the price and availability of antineoplastic medicines, hence 
background information was very limited. There was low medicine availability in the public 
sector which affected calculation of the median price ratio comparison between the private and 
public sector. Also affordability was calculated on the wage/salary of the least paid government 
worker, this is not representative enough in an economic environment with a greater than 60% 
unemployment rate. It is difficult to translate the affordability to the generally unemployed 
population. Also the study did not look at the differences in exit prices between the generics 
and brand medicines. This has an impact on the median price ratio and price differences of 
medicines. Some medicines could not have their median price ratio calculated as they do not 
have international reference prices. There is likelihood of worsening availability of 
antineoplastic medicines as the forex situation in Zimbabwe persists. 
Recommendations 
The government should resuscitate local manufacturing industry and facilitate registration of 
generic antineoplastic medicines by local pharmaceutical manufacturers. Continued positive 
strides in government procurement should be commended. However the role of health 
economists should be implored so that cost minimisation is not the only considered means of 
procurement but cost effectiveness is also considered.  More studies needs to be done that look 
at the cost and availability of antineoplastic medicines on a nationwide scale. More elaborate 
studies need to be done that give information on the feasibility of pricing models here in 
Zimbabwe.  
The generic medicines policy should also be used as the median prices of generic medicines 
tend to be low as compared to the brand medicines. The MRPs of antineoplastic medicines in 
Zimbabwe for both the private and public institutions have shown that the medicines are not 
highly priced compared to the IRP taking into consideration the fact that we are not 
manufacturing any of the antineoplastic medicines. 
Generally availability of antineoplastic medicines amongst other essential medicines was very 
low in the public sector and also there were very few institutions that had more than 50% 
availability in private pharmacies. There is also a need for government health levy also being 
used for subsidisation of acquisition of oncology products so that they would be cheaper to the 
general public. 
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These results shows that antineoplastic medicines were highly unaffordable taking into 
consideration the poverty datum line in Zimbabwe and the high unemployment rate. However 
the root cause analysis of the high prices had nothing to do with the mark-up of medicines in 
retail and public pharmacies, as mark ups of 30 to 50% were noted during the study. It was 
more on the acquisition costs of the imported medicine in the supply chain. 
Government needs to capacitate local industry on antineoplastic medicines dossier acquisition 
and manufacturing industry resuscitation so that products are manufactured locally. This 
reduces transport costs which also imparts on the overall cost of medicines. This also increases 
competition and hence reduce prices and the cost burden on the patients. 
More studies on availability and affordability of medicines needs to be done in Zimbabwe to 
support policy formulation on better availability of medicines. There is need of more research 
on alternative complementary medicines that can positively adjust the quality of life of cancer 
patients at lower prices as compared to the conventional medicines. 
There is need to ensure that there is prescribed policies that guides acquisition of medicines 
within prescribed government policy and approved IRP in public institutions. 
Both the retail sector and public sector should implore pooled procurement and cut on the 
middlemen normally the wholesalers whom sometimes might have exclusive distributorship 
rights with manufacturer. There is need of review of policy of distributorship rights in 
Zimbabwe to increase access to medicines. There is need of ensuring that the applicants of 
medicines in Zimbabwe are manufacturers rather than distributors. This eliminates monopoly 
and hence increase competition. 
Conclusions 
The high median price ratio in the private sector means the antineoplastic medicines in 
Zimbabwe are relatively costly compared to other countries. This been attributed to lack of 
locally manufactured medicines. Government should recapitalise local manufacturers and 
create bilateral partnerships with outside pharmaceutical companies that are already 
manufacturing antineoplastic medicines so that they set up plants locally. There is need of 
immediate consideration of pricing models that benefits both the general public and also 
promote sustainability of private retail players. There is need to improve availability of 
medicines in public institutions and decentralization of palliative care services from the main 
two general hospitals. Currently the exchange rates of the USD to the RTGS are worsening by 
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the day this has affected affordability of medicines given people are earning in RTGS and 
medicines especially in the private sector are sold in USD. The high price and low availability 
impacted access of the antineoplastic medicines on the patients. Low availability of 
antineoplastic medicines in public institutions regardless of the low prices of the medicines, 
meant that the out of pocket fees by patients were considerably high as they still had to source 
for the unavailable medicines. 
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Appendix 1: Medicine Price Data Collection Form 
 
Code Name for Institution………………….  Date…………………………. 
Institution type: Private Pharmacy         Hospital       Clinic  
Generic 
name, 
Dosage 
form 
Strength 
Product 
Type i.e 
Innovator 
Or 
Generic 
Manufacturer  Availability 
Yes or No 
Price of 
recommended 
pack size 
Unit 
price/tab 
Percentage 
Mark-up 
Days 
wage 
 
         
         
         
         
         
 
 
 
Name of Data Collector…………………… Signature 
